Danazol Therapy for Autoimmune Hemolytic Anemia
article
OA: closed
CC0
⤵ 36 in-corpus citations
AI-generated summary
Danazol therapy in autoimmune hemolytic anemia patients effectively raised hematocrit within weeks, allowing for glucocorticoid tapering and demonstrating value for long-term management.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We evaluated the use of danazol in 15 patients with autoimmune hemolytic anemia of the warm antibody type. Danazol, 600 to 800 mg/d, was added to previous regimens or given initially in conjunction with high-dose prednisone treatment. Twelve patients with autoimmune hemolytic anemia associated with nonmalignant disorders or idiopathic autoimmune hemolytic anemia and 1 of 3 patients with underlying neoplasms showed a rise in hematocrit within 1 to 3 weeks. Thereafter, glucocorticoid doses were tapered to a minimum requirement or stopped. Once remission was sustained, the dose of danazol was reduced to 200 to 400 mg/d. Although levels of erythrocyte-bound IgG antibody and C3 decreased with therapy, only the decrease in C3 was statistically significant (p less than 0.05) in this limited study. Danazol was effective regardless of the severity of the disorder and success or failure of previous treatments. Danazol is valuable in the treatment of autoimmune hemolytic anemia and may be better suited than glucocorticoids for long-term management.
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (9)
- Danazol via openalex
- Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. via openalex
- W2409338822 via openalex
- doi:10.1016/s0065-230x(08)60176-1 via openalex
- doi:10.1093/ajcp/79.2.182 via openalex
- doi:10.7326/0003-4819-87-2-210 via openalex
- doi:10.1056/nejm198306093082306 via openalex
- doi:10.7326/0003-4819-93-6-809 via openalex
- doi:10.1146/annurev.me.28.020177.001503 via openalex
Cited by (29)
- Danazol 2022
- Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia 2015
- Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych 2014
- Effects of Danazol on Clinical Improvement of Patients with Human T-cell Lymphotropic Virus Type I Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A Placebo-Controlled Clinical Trial. 2013
- Danazol treatment of myelodysplastic syndromes 2008
- Danazol therapy for aplastic anemia refractory to immunosuppressive therapy 2007
- Hemolytic anemia due to warm autoantibodies 2007
- Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients 2005
- Potential involvement of the immune system in the development of endometriosis 2003
- Remission of transformed myelodysplastic syndrome with fibrosis after danazol therapy 2002
- Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome 2002
- Danazol treatment of idiopathic myelofibrosis with severe anemia. 2000
- Danazol for paroxysmal nocturnal hemoglobinuria 1997
- Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases 1996
- Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases 1996
- A review of 76 patients with myelodysplastic syndromes treated with danazol 1994
- Danazol in autoimmune haemolytic anaemia 1993
- Danazol: <i>in vitro</i> effects on human hemopoiesis and <i>in vivo</i> activity in hypoplastic and myelodysplastic disorders 1991
- Danazol in treatment of lupus thrombocytopenia. 1991
- Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM): Treatment with an Anabolic Steroid Danazol 1991
- Chronic actinic dermatitis responding to danazol 1991
- Danazol for Evan's Syndrome Due to SLE 1990
- Danazol in treatment of angio-immunoblastic lymphadenopathy 1989
- The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol 1988
- Possible Response of Paroxysmal Cold Hemoglobinuria to Danazol 1987
- DANAZOL‐INDUCED THROMBOCYTOPENIA 1987
- Danazol in the treatment of myelodysplastic syndromes 1987
- Efficacy of danazol in pure red cell aplasia 1986
- Danazol Therapy in Myelodysplasia 1985
Source provenance
- openalex
- last seen: 2026-05-10T10:35:03.967074+00:00
- unpaywall
- last seen: 2026-10-06T06:46:56.404536+00:00
License: CC0
· commercial use OK